New research reveals that patients who stop using new GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds at a significantly accelerated pace than those who halt traditional diet and exercise regimens.
Published data in a leading medical journal shows that while obese people often shed about a fifth of their total mass while on the medication, the mass comes back at an average rate of nearly a kilo each month after stopping.
"Users buying these treatments should be aware of the danger of fast weight regain when the treatment is stopped," warns lead investigator Dr. Susan Jebb.
This pace of recovery means a return to starting weight within about 18 months.
Comparing Therapies
The study, which reviewed dozens of studies involving over 9,000 of patients, compared the effects of the injectable medications with conventional dieting.
Scientists point out that individuals who lose weight through dieting usually see a more gradual weight regain—perhaps 0.1 kg a month—once they finish.
Understanding the Fast Regain
Doctors believe the mode of action of the injections explains the accelerated regain.
GLP-1 drugs mimic a natural hormone called GLP-1, which helps regulate appetite.
"Sustained high doses of the hormone concentrations several times higher than normal could lead to the system to generate a reduced amount of its endogenous GLP-1, and could diminish responsiveness to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this medication leads to hunger is unsuppressed, making excessive eating a significant risk."
A Chronic Condition?
Health authorities advise the injections for individuals with obesity-related medical conditions, accompanied by recommended lifestyle changes.
A number of clinicians argue that, considering the likelihood of weight regain, the treatment might need to be ongoing.
This perspective is echoed by pharmaceutical companies, who note that the findings "emphasize the chronic nature of obesity," akin to managing diseases like high blood pressure.
User Testimonies
Users who have stopped the medication report a sudden return of appetite.
"I experienced something activating and I was suddenly ravenous," recalled one woman.
The struggle is worsened if individuals have not adopted sustainable lifestyle or habit changes during therapy.
Widespread Adoption
Recent estimates indicate that a significant number of people in the UK have used weight-loss jabs in the past year, with desire being substantial.
- Use is higher among females compared to males.
- The middle-aged demographic shows the greatest level of interest.
- Many obtain the medications through private healthcare rather than the NHS.
Finally, clinicians caution that while GLP-1 drugs are potent tools for weight loss, they are not a standalone cure and maintained weight loss relies on ongoing behavioural changes.
